The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
Sign Up to like & getrecommendations! Published in 2022 at "Science Signaling"
DOI: 10.1126/scisignal.abn2707
Abstract: Proteolysis-targeting chimeras (PROTACs) are a promising new class of drugs that selectively degrade cellular proteins of interest. PROTACs that target oncogene products are avidly being explored for cancer therapies, and several are currently in clinical… read more here.
Keywords: mdr1; resistance protacs; resistance; drug ... See more keywords